Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells $36,003.90 in Stock

Posted by Alphonse Anthony on Dec 26th, 2025

Clene Inc. (NASDAQ:CLNN – Get Free Report) major shareholder Chidozie Ugwumba sold 5,582 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $6.45, for a total transaction of $36,003.90. Following the completion of the transaction, the insider owned 387,568 shares of the company’s stock, valued at $2,499,813.60. The trade was a 1.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

On Monday, December 22nd, Chidozie Ugwumba sold 4,367 shares of Clene stock. The shares were sold at an average price of $6.54, for a total transaction of $28,560.18.
On Wednesday, December 3rd, Chidozie Ugwumba sold 56,577 shares of Clene stock. The shares were sold at an average price of $7.86, for a total value of $444,695.22.
On Thursday, December 18th, Chidozie Ugwumba sold 5,816 shares of Clene stock. The stock was sold at an average price of $6.33, for a total value of $36,815.28.
On Wednesday, December 17th, Chidozie Ugwumba sold 2,884 shares of Clene stock. The stock was sold at an average price of $6.61, for a total value of $19,063.24.
On Tuesday, December 16th, Chidozie Ugwumba sold 7,030 shares of Clene stock. The shares were sold at an average price of $6.31, for a total transaction of $44,359.30.
On Monday, December 15th, Chidozie Ugwumba sold 10,580 shares of Clene stock. The stock was sold at an average price of $6.49, for a total transaction of $68,664.20.
On Friday, December 12th, Chidozie Ugwumba sold 7,603 shares of Clene stock. The shares were sold at an average price of $6.79, for a total transaction of $51,624.37.
On Thursday, December 11th, Chidozie Ugwumba sold 10,907 shares of Clene stock. The shares were sold at an average price of $6.81, for a total transaction of $74,276.67.
On Wednesday, December 10th, Chidozie Ugwumba sold 9,921 shares of Clene stock. The stock was sold at an average price of $6.42, for a total transaction of $63,692.82.
On Tuesday, December 9th, Chidozie Ugwumba sold 15,031 shares of Clene stock. The shares were sold at an average price of $5.95, for a total value of $89,434.45.

Clene Trading Up 1.1%

Clene stock opened at $6.33 on Friday. The stock has a 50-day moving average price of $8.34 and a two-hundred day moving average price of $6.27. Clene Inc. has a 12 month low of $2.28 and a 12 month high of $13.50. The company has a market capitalization of $65.39 million, a PE ratio of -1.87 and a beta of 0.79.

Clene (NASDAQ:CLNN – Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. As a group, analysts predict that Clene Inc. will post -5.19 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CLNN has been the subject of a number of analyst reports. UBS Group restated a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. D. Boral Capital restated a “buy” rating and issued a $23.00 price target on shares of Clene in a research report on Wednesday, December 10th. Benchmark reiterated a “buy” rating on shares of Clene in a research report on Thursday, December 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a research note on Tuesday, October 14th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Clene has an average rating of “Moderate Buy” and a consensus target price of $32.60.

Read Our Latest Analysis on CLNN

Institutional Trading of Clene

Several large investors have recently modified their holdings of CLNN. Jones Financial Companies Lllp acquired a new position in shares of Clene during the 3rd quarter valued at $29,000. Jane Street Group LLC bought a new stake in Clene in the second quarter valued at $47,000. Lunt Capital Management Inc. raised its holdings in shares of Clene by 71.2% during the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock valued at $199,000 after purchasing an additional 21,217 shares during the period. Finally, Scoggin Management LP boosted its position in shares of Clene by 42.8% during the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock worth $558,000 after purchasing an additional 42,750 shares in the last quarter. Institutional investors and hedge funds own 23.28% of the company’s stock.

Clene Company Profile

(Get Free Report)

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).